{"id":3036,"date":"2019-10-10T04:53:16","date_gmt":"2019-10-10T02:53:16","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=3036"},"modified":"2024-02-19T14:45:58","modified_gmt":"2024-02-19T13:45:58","slug":"difficult-to-treat-infections-and-antimicrobians-use","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/translational-medicine-area\/infectious-disease-and-transplantation-program\/difficult-to-treat-infections-and-antimicrobians-use\/","title":{"rendered":"Difficult to Treat Infections and Antimicrobians Use"},"content":{"rendered":"\n

\n\t\tDifficult to Treat Infections and Antimicrobians Use\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The Difficult to Treat Infections and Antimicrobians Use research group covers a diverse series of lines of clinical and experimental research, all of which have proved to be difficult in terms of finding an effective treatment and optimal use of antimicrobial medicinal products. In all cases, the study aim is to optimise antimicrobial medications, their mechanisms of action and their ability to reach the pathogenic organisms.<\/p>\n

632<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"lo\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tCNS infections
\nMulti-resistant (MR)\u00a0P. aeruginosa\u00a0<\/i>infections
\nOsteoarthritis and osteoarticular implant-associated infections\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Soldevila Boixader,L;Mur,I;Morata,L;Sierra,Y;Rivera,A;Bosch,J;Montero Saez,A et al, Clinical usefulness of quantifying microbial load from diabetic foot ulcers: A multicenter cohort study<\/strong>, Diabetes Res. Clin. Pract., 2022;189109975-109975, doi:10.1016\/j.diabres.2022.109975,<\/p>\n

Haj,CE;Benavent,E;Sierra,Y;Soldevila,L;Rigo Bonnin,R;Torrej\u00f3n,B;Gomez Junyent,J et al, Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus<\/strong>, Int. J. Antimicrob. Agents, 2022;60(4):106664-106664, doi:10.1016\/j.ijantimicag.2022.106664,<\/p>\n

Espindola,R;Vella,V;Benito,N;Mur,I;Tedeschi,S;Rossi,N;Hendriks,J et al, Preoperative and perioperative risk factors, and risk score development for prosthetic joint infection due to Staphylococcus aureus: A multinational matched case-control study<\/strong>, Clin. Microbiol. Infect., 2022;28(10):1359-1366, doi:10.1016\/j.cmi.2022.05.010,<\/p>\n

Esp\u00edndola,R;Vella,V;Benito,N;Mur,I;Tedeschi,S;Zamparini,E;Hendriks,J et al, Rates and Predictors of Treatment Failure in Staphylococcus aureus Prosthetic Joint Infections According to Different Management Strategies: A Multinational Cohort Study-The ARTHR-IS Study Group<\/strong>, Infect. Dis. Ther., 2022;11(6):2177-2203, doi:10.1007\/s40121-022-00701-0<\/p>\n

Cabellos,C;Guillem,L;Pelegrin,I;Tubau,F;Ardanuy,C;Gudiol,F;Ariza,J et al, Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis: Treatment in the Real World and in Guidelines., Antimicrob. Agents Chemother<\/strong>, 2022;66(12):doi:10.1128\/aac.00820-22<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

DURATIOM ACNA168\/21. Eficacia y seguridad de diferentes duraciones de antimicrobianos para el tratamiento las infecciones asociadas al material de osteos\u00edntesis implantado tras fractura de hueso largo (DURATIOM): ensayo aleatorizado multic\u00e9ntrico pragm\u00e1tico de fase 3<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 429350,9. 2022-2025. PI: Murillo Rubio, Oscar.<\/p>\n

19FIS018. Vasculitis cerebral post meningitis neumoc\u00f3cica: Factores relacionados y etiopatogenia<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 111320. 2019-2023. PI: Cabellos M\u00ednguez, Mar\u00eda del Carmen.<\/p>\n

19MEC020. AYUDAS PARA LA FORMACION DE DOCTORES DEL PROGRAMA NACIONAL DE FORMACION DE PROFESORADO UNIVERSITARIO (FPU). MINISTERIO DE EDUCACI\u00d3N Y FORMACI\u00d3N PROFESIONAL<\/strong>. Budget: 81493,77. 2019-2023. PI: Murillo Rubio, Oscar.<\/p>\n

21FIS033. CONTRATOS PARA LA INTENSIFICACION DE LA ACTIVIDAD INVESTIGADORA EN EL SNS<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 60000. 2021-2022. PI: Murillo Rubio, Oscar.<\/p>\n

17ACL190. EFFICACY OF DALBAVANCIN, ALONE AND IN COMBINATION, AGAINST IN VITRO FOREIGN-BODY INFECTION CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS: A PHARMACODYNAMIC STUDY<\/strong>. Budget: 43665,12. 2017- . PI: Murillo Rubio, Oscar.<\/p>\n\t\t\t\t\"Murillo\n

\n\t\tMurillo Rubio, Oscar\n\t<\/h4>\n

\n\t\t\n\t\tomurillo@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Murillo\n

\n\t\tMurillo Rubio, Oscar\n\t<\/h4>\n

\n\t\t\n\t\tomurillo@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"ariza-cardenal-xavier\"\n

\n\t\tAriza Cardenal, Xavier\n\t<\/h4>\n

\n\t\t\n\t\txariza@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Carmen-Cabellos-Minguez\"\n

\n\t\tCabellos M\u00ednguez, M. Carmen\n\t<\/h4>\n

\n\t\t\n\t\tmcabellos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Evelyn-Shaw-Perujo\"\n

\n\t\tShaw Perujo, Evelyn\n\t<\/h4>\n

\n\t\t\n\t\tmcabellos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific Support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t